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Mutations of genes encoding for collagen VI cause various muscle diseases in humans,
including Bethlem myopathy and Ullrich congenital muscular dystrophy. Collagen VI null
(Col6a1−/−) mice are affected by a myopathic phenotype with mitochondrial dysfunction,
spontaneous apoptosis of muscle fibers, and defective autophagy. Moreover, Col6a1−/−
mice display impaired muscle regeneration and defective self-renewal of satellite cells
after injury. Treatment with cyclosporin A (CsA) is effective in normalizing the mitochondr-
ial, apoptotic, and autophagic defects of myofibers in Col6a1−/− mice. A pilot clinical trial
with CsA in Ullrich patients suggested that CsA may increase the number of regenerat-
ing myofibers. Here, we report the effects of CsA administration at 5 mg/kg body weight
every 12 h in Col6a1−/− mice on muscle regeneration under physiological conditions and
after cardiotoxin (CdTx)-induced muscle injury. Our findings indicate that CsA influences
satellite cell activity and triggers the formation of regenerating fibers in Col6a1−/− mice.
Data obtained on injured muscles show that under appropriate administration, regimens
CsA is able to stimulate myogenesis in Col6a1−/− mice by significantly increasing the num-
ber of myogenin (MyoG)-positive cells and of regenerating myofibers at the early stages
of muscle regeneration. CsA is also able to ameliorate muscle regeneration of Col6a1−/−
mice subjected to multiple CdTx injuries, with a concurrent maintenance of the satellite
cell pool. Our data show that CsA is beneficial for muscle regeneration in Col6a1−/− mice.
Keywords: collagen VI, skeletal muscle, congenital muscular dystrophy, animal model, cyclosporin A, muscle
regeneration
INTRODUCTION
Collagen VI is an extracellular matrix protein that forms a
microfibrillar network in the endomysium of skeletal muscle.
The critical role played by this protein in muscle is clearly
shown by collagen VI null (Col6a1−/−) mice, which display an
early onset myopathic phenotype characterized by mitochondr-
ial dysfunction, defective autophagy, and spontaneous apopto-
sis of muscle fibers (Bonaldo et al., 1998; Irwin et al., 2003;
Grumati et al., 2010). Cyclosporin A (CsA) is a well-known
immunosuppressant drug that was found to have multiple ben-
eficial effects on the myopathic phenotype of Col6a1-/- mice,
including (i) decreased opening of the mitochondrial perme-
ability transition pore; (ii) rescue of myofiber apoptosis; (iii)
stimulation of autophagy in muscle fibers; and (iv) recovery of
muscle strength (Irwin et al., 2003; Grumati et al., 2010). Muta-
tions of COL6 genes in humans cause several muscle disorders,
including Bethlem myopathy and Ullrich congenital muscular
dystrophy (Lampe and Bushby, 2005). A pilot clinical trial in
Ullrich and Bethlem patients showed that CsA favorably affects
mitochondrial function and dramatically decreases the incidence
of apoptosis in muscle fibers. Notably, a significant increase in
the number of regenerating myofibers was observed in younger
patients undergoing CsA treatment, suggesting that CsA may also
increase the overall efficiency of muscle regeneration in patients
(Merlini et al., 2008, 2011).
Muscle regeneration relies on the presence of satellite cells,
which are quiescent under physiological conditions but become
activated upon damage, thus undergoing proliferation and ter-
minal differentiation. At the same time, a subset of activated
satellite cells returns to the quiescent state in their original niche
under the basal lamina, through a self-renewal process (Tedesco
et al., 2010). The differentiation of satellite cells is regulated by
a number of transcription factors, where Pax7 is required for
satellite cell specification and survival, whereas MyoD, myogenin
(MyoG), and MRF4 are essential for satellite cell proliferation and
differentiation (Buckingham and Rigby, 2014). Terminal differ-
entiation coincides with the abundant synthesis of myosin heavy
chain (MHC). The cardiotoxin (CdTx) injury model is widely
used to investigate skeletal muscle regeneration (Chargé and Rud-
nicki, 2004; Shi and Garry, 2006). We recently demonstrated that
collagen VI is a critical component of satellite cell niche and
that ablation of collagen VI leads to impaired muscle regenera-
tion and reduced satellite cell self-renewal after injury (Urciuolo
et al., 2013). Studies performed in tibialis anterior (TA) mus-
cle showed that Col6a1−/− mice undergo a marked depletion of
the satellite cell pool 7 days after CdTx injection, and this defect
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becomes much more dramatic after multiple rounds of CdTx
injury (Urciuolo et al., 2013). Given the effects displayed by CsA
in collagen VI-deficient mice and Ullrich/Bethlem patients (Irwin
et al., 2003; Merlini et al., 2008), here we analyzed in detail the out-
comes of CsA administration on muscle regeneration and satellite
cells in Col6a1−/− mice under physiological conditions and after
CdTx-induced injury.
MATERIALS AND METHODS
MICE
We performed experiments in wild-type mice of the inbred
C57BL/6NCrl strain and in Col6a1−/−mice that were backcrossed
in the C57BL/6NCrl strain for eight generations (Irwin et al.,
2003). All data were obtained from 6-month-old mice. Mice were
housed in individual cages in an environmentally controlled room
(23°C, 12 h light/12 h dark cycle) and provided food and water
ad libitum. Mouse procedures were approved by the Ethics Com-
mittee of the University of Padova and authorized by the Italian
Ministry of Health.
IN VIVO TREATMENTS
Cyclosporin A (Sandimmun 50 mg/ml, Novartis) was dissolved
in olive oil and a stock solution at a concentration of 10 mg/ml
was prepared. For CsA administration under physiological con-
ditions, mice were subjected to intraperitoneal (i.p.) injection
of vehicle (olive oil) or CsA at 5 mg/kg body weight every 12 h
for 10 days. In experiments with higher dosage CsA, mice were
subjected to i.p. injection of vehicle or CsA at 25 mg/kg body
weight every 24 h for 10 days. Animals were sacrificed 12 h after
the last administration of CsA or vehicle. For single CdTx injury
(Couteaux et al., 1988), mice were treated by i.p. injection with
vehicle or CsA at 5 mg/kg body weight every 12 h for 10 days. At
day 4 from the first administration of vehicle or CsA, mice were
anesthetized with isoflurane (Merial) and TA muscles injected with
30µl CdTx (Naja mossambica mossambica, 10µM; Sigma). Anal-
gesia (Rimadyl) was administered subcutaneously for 3 days and
mice were sacrificed 7 days after muscle damage (i.e., 10 days after
the first injection of vehicle or CsA). For multiple injury experi-
ments, TA muscles were subjected to three distinct injections of
CdTx, each one every 30 days. Four days before the third CdTx
injection, mice were treated by i.p. injection with vehicle or CsA
at 5 mg/kg body weight every 12 h for 10 days. Mice were sacri-
ficed 30 days after the third CdTx injury (i.e., 24 days after the last
injection of vehicle or CsA).
HISTOLOGICAL ANALYSIS
Tibialis anterior muscles were isolated from mice, frozen in liq-
uid nitrogen, weighted on a precision balance, and kept at −80°C
until use. Cross-sections (10µm thick) were used and processed
for hematoxylin–eosin or Azan-Mallory staining following stan-
dard protocols. Samples were analyzed with a Zeiss Axioplan light
microscope equipped with Leica DC500 digital camera. Myofiber
cross-sectional area and the area of fibrosis were evaluated with
the IM1000 software (Leica).
ISOLATION OF EXTENSOR DIGITORUM LONGUS SINGLE MYOFIBERS
We carefully dissected extensor digitorum longus (EDL) mus-
cles from 6-month-old mice and subjected them to enzymatic
digestion with collagenase I (2 mg/ml, Gibco) for 80 min at
37°C. We blocked the digestion with Dulbecco’s Modified
Eagle Medium (DMEM, Sigma), supplemented with 0.2 M l-
glutamine (Invitrogen), 1:100 penicillin-streptomycin (Invitro-
gen), 1:100 fungizone (Invitrogen), and 10% horse serum (Gibco),
and gently released single myofibers from muscles. Every 15–
25 min, undamaged and non-contracted fibers were transferred
in a new dish containing fresh medium, and this procedure
was repeated five times in order to remove debris and inter-
stitial cells. Freshly isolated fibers were finally fixed in 4%
paraformaldehyde in PBS for 15 min and maintained at 4°C in
PBS until use.
IMMUNOFLUORESCENCE
For immunofluorescence on muscle sections, frozen TA sections
(7µm) were fixed for 20 min with 4% paraformaldehyde in
PBS and permeabilized for 6 min with cold methanol. For the
unmasking of Pax7 and MyoG, slides were treated twice with
0.01 M citric acid (pH 6) at 90°C for 5 min. For mouse anti-
bodies staining, samples were first incubated for 2.5 h with 4%
bovine serum albumin (BSA IgG-Free, Jackson Immunoresearch)
in PBS and then treated for 30 min with a blocking solution
containing 0.05 mg/ml Fab fragment anti-mouse IgG (Jackson
Immunoresearch). When mouse antibodies were not used, sam-
ples were only incubated for 1 h at room temperature with 4%
bovine serum albumin in PBS. After the blocking step, sam-
ples were incubated with primary antibodies at 4°C overnight.
The following primary antibodies were used: mouse anti-Pax7
(1:20; Developmental Studies Hybridoma Bank); mouse anti-
MyoG (F5D, 1:15; Developmental Studies Hybridoma Bank);
mouse anti-embryonic MHC (eMHC) (F1.652, 1:20; Develop-
mental Studies Hybridoma Bank); rabbit anti-laminin (L9393,
1:800; Sigma). After washing, samples were incubated with the
appropriate secondary antibody for 1 h at room temperature.
Secondary antibodies used were biotinylated anti-mouse (115-
007-003, 1:1000), Cy2 or Cy3 anti-mouse (115-226-062, 1:500,
or 115-165-006, 1:1000), Cy2 or Cy3 anti-rabbit (111-225-144,
1:500, or 115-165-006, 1:1000) (all Jackson Immunoresearch). To
reveal the biotinylated antibody, Cy2 or Cy3 streptavidin (016-220-
084, 1:1500, or 016-160-084, 1:2500; Jackson Immunoresearch)
was used. For immunofluorescence of EDL single myofibers,
cells were permeabilized with 0.5% Triton X-100 in PBS, treated
with 20% goat serum (Invitrogen) in PBS for 1 h, and incu-
bated at 37°C for 1 h or at 4°C overnight with mouse anti-Pax7
antibody (1:20; Developmental Studies Hybridoma Bank). After
washing, samples were incubated with the appropriate secondary
antibody as described above. Nuclei were stained with Hoechst
33258 (Sigma). Samples were analyzed with a Zeiss Axioplan Leica
DC500 epifluorescence microscope or with a Leica SP5 confocal
microscope.
TUNEL
For apoptosis analysis on TA cryosections, the DeadEnd™ Fluo-
rometric TUNEL assay (Promega) was used. Samples were fixed
for 15 min with 4% paraformaldehyde, permeabilized for 5 min
with 0.5% Triton X-100, and processed following manufacturer
instructions.
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FIGURE 1 | Cyclosporin A induces muscle regeneration and increases
satellite cell number in Col6a1−/− mice. (A) Schematic diagram of CsA
treatment. Wild-type and Col6a1−/− mice were treated with vehicle or with
CsA (5 mg/kg body weight) every 12 h for 10 days. Animals were sacrificed
12 h after the last administration of CsA or vehicle. (B) Mean
cross-sectional area of regenerating centrally nucleated myofibers in TA
muscles derived from wild-type and Col6a1−/− mice treated with vehicle or
CsA. Fibers were divided into four size ranges, and at least 150 centrally
nucleated myofibers were analyzed for each group. Error bars indicate
SEM (*P <0.05 for Col6a1−/− CsA vs. Col6a1−/− vehicle; n=3–4, each
group). (C) Left panel, representative images of immunofluorescence
labeling for laminin (green) and Pax7 (red) in TA cross-sections of
CsA-treated Col6a1−/− mice. The arrowhead points at one satellite cell,
shown at higher magnification in the inset. Nuclei were stained with
Hoechst (blue). Scale bar, 25µm. Right panel, quantification of total
Pax7-positive cells and of satellite cells, calculated as the number on 100
myofibers in TA muscles derived from wild-type and Col6a1−/− mice
treated with vehicle or CsA. Error bars indicate SEM (*P <0.05; n=5–7,
each group). CNF, centrally nucleated fibers; CSA, cross-sectional area;
SCs, satellite cells; WT, wild-type.
STATISTICAL ANALYSES
Data are expressed as means± SEM. We determined statistical
significance by unequal variance Student’s t -test, and a P value of
<0.05 was considered statistically significant.
RESULTS
CsA INDUCES MUSCLE REGENERATION IN Col6a1−/− MICE UNDER
PHYSIOLOGICAL CONDITIONS
To investigate the effects of CsA administration in Col6a1−/−mice
under physiological conditions, we subjected animals to i.p. injec-
tion of vehicle or CsA at 5 mg/kg body weight every 12 h and
analyzed muscles after 10 days of treatment (Figure 1A). This
dosage of CsA was previously found to trigger a marked ameliora-
tion of the myopathic phenotype of Col6a1−/− mice, with rescue
from mitochondrial depolarization and apoptosis and reactiva-
tion of the autophagic flux in muscle fibers (Irwin et al., 2003;
Grumati et al., 2010). To evaluate whether this CsA treatment
triggered de novo formation of myofibers in Col6a1−/− mice, we
first analyzed the cross-sectional area of regenerating, centrally
nucleated fibers in TA muscle, by dividing regenerating myofibers
into four different size ranges. Unlike wild-type animals, CsA
treatment led to a significant increase of the percentage of regen-
erating myofibers with small area (<500µm2) in Col6a1−/− mice
when compared to vehicle-treated Col6a1−/− animals (Figure 1B).
These data were also confirmed by immunofluorescence analysis
for eMHC, an established marker of newly forming fibers (Ciciliot
and Schiaffino, 2010). Immature myofibers expressing eMHC were
present in TA muscles of Col6a1−/−mice treated with CsA, but not
in those treated with vehicle (Figure S1A in Supplementary Mater-
ial). Based on these results, we evaluated the number of myogenic
cells by performing immunostaining for Pax7. CsA administra-
tion increased the total number of Pax7-positive cells and also the
number of satellite cells (i.e., Pax7-positive cells located under-
neath the basal lamina) in Col6a1−/− TA but not in wild-type
TA (Figure 1C). These data were confirmed by analyzing freshly
isolated EDL myofibers, which showed a significant increase in
the number of Pax7-positive cells on myofibers derived from CsA-
treated Col6a1−/−mice when compared to vehicle-treated animals
(Figure S1B in Supplementary Material). To assess whether the
increased number of Pax7-positive cells in Col6a1−/− animals was
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FIGURE 2 | Continuous administration of CsA during a single CdTx
injury stimulates muscle differentiation in Col6a1−/− mice.
(A) Schematic diagram of CsA treatment and CdTx injury. Wild-type and
Col6a1−/− mice were treated with vehicle or CsA (5 mg/kg body weight)
every 12 h for 10 days. Four days after the first injection of vehicle or CsA,
TA muscles were injured with CdTx and drug treatment continued for
other 7 days. Animals were sacrificed 12 h from the last administration of
CsA or vehicle. (B) Left panels, representative images of
immunofluorescence labeling for laminin (green) and Pax7 (red) in
7-day-post-injury TA cross-sections of wild-type and Col6a1−/− mice
treated with vehicle or CsA. Scale bar, 25µm. Right panel, quantification
of total Pax7-positive cells and of satellite cells, calculated as the number
on 100 myofibers in 7-day-post-injury TA muscles of wild-type and
Col6a1−/− mice treated with vehicle or CsA. Error bars indicate SEM
(**P < 0.01; *P <0.05; n.s. not significant; n=3–5, each group). (C) Left
panels, representative images of immunofluorescence labeling for laminin
(green) and MyoG (red) in 7-day-post-injury TA cross-sections of Col6a1−/−
mice treated with vehicle or CsA. Nuclei were stained with Hoechst (blue).
The arrowheads point at MyoG-positive cells outside the basal lamina, and
the asterisks mark MyoG-positive cells located underneath the basal
lamina (corresponding to myogenic cells that are undergoing fusion).
(Continued)
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FIGURE 2 | Continued
Scale bar, 50µm. Right panel, quantification of total MyoG-positive cells,
calculated as the number on 100 myofibers in 7-day-post-injury TA muscles of
wild-type and Col6a1−/− mice treated with vehicle or CsA. Error bars indicate
SEM (*P <0.05; n=3–5, each group). (D) Left panels, representative images
of immunofluorescence for laminin (green) and eMHC (red) in
7-day-post-injury TA cross-sections of wild-type and Col6a1−/− mice treated
with vehicle or CsA. Nuclei were stained with Hoechst (blue). Scale bar,
50µm. Right panel, quantification of the number of eMHC-positive myofibers
per regenerating area in 7-day-post-injury TA cross-sections of wild-type and
Col6a1−/− mice treated with vehicle or CsA. Error bars indicate SEM
(**P <0.01; n=3–5, each group). SCs, satellite cells; WT, wild-type.
only provided by this drug dosage or could be also elicited by
higher CsA concentrations known to cause strong immunosup-
pressive effects (Homan et al., 1980), we subjected mice to i.p.
injection of CsA at 25 mg/kg body weight every 24 h for 10 days.
Interestingly, at this higher dosage, CsA led to a dramatic decrease
in the number of total Pax7-positive cells and of satellite cells both
in wild-type and in Col6a1−/− mice when compared to vehicle-
treated animals (Figure S1C in Supplementary Material). These
results highlight the relevance of CsA dosage in inducing beneficial
effects in Col6a1−/− muscles and accordingly with previous stud-
ies carried out with the immunosuppressive drug FK506 (Irwin
et al., 2003), they suggest that immunosuppression exacerbates
the phenotype of Col6a1−/− mice.
CONTINUOUS ADMINISTRATION OF CsA DURING CdTx INJURY
STIMULATES THE EARLY PHASES OF MUSCLE DIFFERENTIATION IN
Col6a1−/− MICE
To further assess the capability of CsA to ameliorate the muscle
regenerative defects of Col6a1−/− mice, we carried out CsA treat-
ment under experimentally induced muscle injury. Toward this
aim, wild-type and Col6a1−/− mice were treated for 10 days with
vehicle or CsA at 5 mg/kg body weight every 12 h; 4 days after the
start of treatment, TA muscles were subjected to CdTx damage and
mice were sacrificed 7 days after injury (Figure 2A). TUNEL assay
showed that the incidence of apoptotic nuclei 7 days after CdTx
injection was very low in wild-type TA, in agreement with the con-
cept that myofiber demise is almost completed at this stage from
injury (Hawke et al., 2003). Conversely, Col6a1−/− TA showed a
higher number of TUNEL-positive myonuclei 7 days after injury,
and CsA administration was able to significantly decrease the
incidence of apoptotic myofibers triggered by CdTx injury in
Col6a1−/− TA muscles (Figure S2 in Supplementary Material).
We next evaluated the number of myogenic cells by immunoflu-
orescence for the Pax7 and MyoG markers. CsA administration
led to a significant decrease in the number of total Pax7-positive
cells in both wild-type and Col6a1−/− injured TA, without any
significant change in the number of satellite cells (i.e., Pax7-
positive cells located underneath basal lamina) (Figure 2B). This
response was paralleled by a significant increase of the total num-
ber of MyoG-positive cells in injured TA muscles of CsA-treated
Col6a1−/− mice when compared to vehicle-treated Col6a1−/−
mice, whereas wild-type injured TA muscles did not show any
significant difference in MyoG positivity between vehicle and
CsA-treated animals (Figure 2C). Additionally, Col6a1−/− mice
treated with CsA showed an increased number of regenerating
myofibers expressing eMHC, whereas no differences in eMHC-
positive regenerating myofibers were found in wild-type animals
(Figure 2D). As the defective satellite self-renewal of Col6a1−/−
mice is strictly dependent on the lack of extracellular collagen VI
and on the lower muscle stiffness (Urciuolo et al., 2013), it was
not surprising to observe that in this experimental condition CsA
does not display any overt effect on satellite cell maintenance. On
the other hand, the remarkable increase in the number of differ-
entiated (i.e., MyoG-positive) myogenic cells, together with the
higher number of newly forming (i.e., eMHC-positive) myofibers,
indicates that CsA administration is able to improve muscle dif-
ferentiation upon damage in the Col6a1−/− myopathic mouse
model.
ADMINISTRATION OF CsA DURING REPEATED MUSCLE INJURY
COUNTERACTS MUSCLE LOSS AND FIBROSIS AND PRESERVES THE
SATELLITE CELL POOL IN Col6a1−/− MICE
Although muscles of Col6a1−/− animals display a delayed regen-
eration after injury, we have previously shown that at 30 days
after CdTx injury they are still able to complete the regeneration
process (Urciuolo et al., 2013). However, and at difference from
wild-type mice, the capability of Col6a1−/− animals to undergo
muscle regeneration and preserve the satellite cell pool is lost after
multiple muscle injuries, leading to a severe loss of muscle mass
(Urciuolo et al., 2013). Therefore, we investigated whether CsA
is able to counteract the defective muscle regeneration and the
depletion of the satellite cell pool triggered by multiple injuries
in Col6a1−/− mice. Toward this aim, we subjected TA muscles of
wild-type and Col6a1−/− mice to three rounds of CdTx injury.
Animals were treated for 10 days with vehicle or CsA at 5 mg/kg
body weight every 12 h during the third injury and sacrificed
30 days after the last injury (Figure 3A). Interestingly, CsA admin-
istration was highly effective in reducing the extensive muscle
fibrosis triggered by triple injury in Col6a1−/− mice (Figure 3B).
The beneficial effects of CsA in Col6a1−/− muscles undergoing
multiple injuries were also confirmed by the increased myofiber
cross-sectional area and by the improvement of the muscle mass
in CsA-treated Col6a1−/− mice when compared to vehicle-treated
Col6a1−/− mice (Figure S3 in Supplementary Material). Notably,
CsA administration led to marked increase of both total Pax7-
positive cell number and satellite cell number in Col6a1−/− TA
muscles subjected to multiple injuries (Figures 3C,D). Altogether,
these results show that at this regimen CsA is capable to preserve
not only muscle fibers but also the satellite cell pool of collagen
VI-deficient mice.
DISCUSSION
In the present study, we evaluated the potential beneficial effects
exerted by CsA on skeletal muscle regeneration in Col6a1−/−
mice, both under physiological condition and after muscle dam-
age. The rationale for this study was based on previous findings
in patients affected by collagen VI myopathies, suggesting that
besides counteracting myofiber apoptosis and mitochondrial dys-
function, CsA treatment may also increase muscle regeneration
(Merlini et al., 2008, 2011). In addition, our recent findings
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FIGURE 3 | Administration of CsA during a triple muscle injury
counteracts muscle loss and fibrosis and preserves the satellite cell
pool in Col6a1−/− mice. (A) Schematic diagram of CsA treatment and
CdTx injuries. TA muscles of wild-type and Col6a1−/− mice were given three
repeated injections of CdTx every 30 days. Four days before the last injury,
Col6a1−/− mice were treated with vehicle or CsA (5 mg/kg body weight)
every 12 h for 10 days. Mice were sacrificed 30 days after the third injury
(i.e., 24 days from the last administration of vehicle or CsA). (B) Left panels,
Azan-Mallory staining of triple injured TA cross-sections from wild-type and
Col6a1−/− mice treated with vehicle or CsA. Scale bar, 50µm. Right panel,
quantification of the fibrotic area in triple-injured TA cross-sections from
wild-type and Col6a1−/− mice treated with vehicle or CsA. Error bars
indicate SEM (**P <0.01; *P <0.05; n=4–8, each group).
(C) Representative images of immunofluorescence labeling for laminin
(red) and Pax7 (green) in triple-injured TA cross-sections from wild-type and
Col6a1−/− treated with vehicle or CsA. Arrows point at Pax7-positive nuclei.
Nuclei were stained with Hoechst (blue). Scale bar, 100µm.
(D) Quantification of total Pax7-positive cells and of satellite cells,
calculated as the number on 100 myofibers in triple-injured TA
cross-sections from wild-type and Col6a1−/− mice treated with vehicle or
CsA. Error bars indicate SEM (**P <0.01; n=4–8, each group). SC,
satellite cells; WT, wild-type.
showed impaired regeneration and defective satellite cell self-
renewal in collagen VI-deficient muscles (Urciuolo et al., 2013).
Therefore, we investigated how CsA treatment impacts on the
regeneration of collagen VI-deficient mice. Under physiological
conditions, CsA was capable to amplify the pool of total Pax7-
positive cells and of satellite cells and increased the amount of
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newly formed centrally nucleated myofibers, thus suggesting a
new role for CsA in stimulating myogenesis in Col6a1−/− mus-
cles. Notably, these beneficial effects were dose-dependent, as they
were observed at 10 mg/kg/day but not at a higher immunosup-
pressant dose (25 mg/kg/day), which conversely had a negative
impact on the satellite cell pool. These data are in agreement
with previous results in which the same protocol of CsA admin-
istration was found to desensitize the mitochondrial permeabil-
ity transition pore and reduce myofiber apoptosis in Col6a1−/−
mice (Irwin et al., 2003). Although we previously demonstrated
that CsA stimulates autophagy in skeletal myofibers (Grumati
et al., 2010), the increased number of satellite cells in muscles
of CsA-treated Col6a1−/− animals is not a direct consequence
of a stimulatory effect on autophagy. Indeed, reactivation of the
autophagic flux in Col6a1−/− mice by different pharmacologi-
cal or dietary treatments does not exert any significant effect on
satellite cells (Urciuolo et al., 2013). Our present findings are con-
sistent with the strong amelioration of the myophatic phenotype
in Col6a1−/−mice following CsA administration and indicate that
besides decreasing mitochondrial dysfunction and apoptosis and
reactivating autophagy in muscle fibers (Irwin et al., 2003; Grumati
et al., 2010), the drug is also able to increase the pool of functional
Pax7-positive cells and stimulate the formation of newly formed
fibers.
The beneficial effects exerted by CsA on the regeneration capa-
bilities of Col6a1−/− mice become very evident under experi-
mentally induced single and multiple muscle injuries. Our data
indicate that CsA is capable to induce myogenesis in Col6a1−/−
mice after muscle damage. In fact, when TA muscles were dam-
aged during a continuous CsA administration, analysis at 7 days
post-injury showed that CsA elicits a significant increase in the
number of MyoG-positive cells and of regenerating myofibers in
Col6a1−/− muscles. Interestingly, this response is not associated
with an improvement of the number of satellite cells, suggesting
that under these conditions CsA is unable to ameliorate satellite
cell self-renewal. The effect of CsA on muscle regeneration was
even more remarkable when we exacerbated the muscle pheno-
type of Col6a1−/−mice through triple CdTx damage. Our findings
indicate that CsA is protective against fibrotic tissue formation,
maybe exerting this effect through an indirect regulation of the
inflammatory state that occurs during muscle regeneration (Ser-
rano et al., 2011). A similar beneficial effect of CsA in reducing
muscle fibrosis was reported for mdx mice undergoing exercise
(De Luca et al., 2005). Furthermore, CsA administration was able
to counteract the loss of satellite cells elicited by repeated muscle
injuries in Col6a1−/− animals, concurrently guaranteeing myo-
genic differentiation, as confirmed by the increase of myofiber
cross-sectional area and muscle mass. Although it was beyond
the scope of this study to dissect the mechanism(s) through which
CsA leads to increased satellite cell number in Col6a1−/−mice after
repeated injuries, it can be hypothesized that CsA administration
may not directly influence the self-renewal capability of satellite
cells and that the preservation of satellite cell pool may be medi-
ated by an increase of their survival. This assumption is supported
by the fact that the defective satellite cell self-renewal of Col6a1−/−
mice is strictly dependent on the lack of collagen VI itself and its
consequences on muscle stiffness (Urciuolo et al., 2013) and that
CsA treatment is able to reduce apoptosis in Col6a1−/− muscles
(Irwin et al., 2003). To our knowledge, no literature work has
investigated in detail the effects of in vivo CsA administration on
stem cell homeostasis in skeletal muscles. A recent study reported
some beneficial effects of CsA on neuronal stem cells, showing that
in vivo CsA administration increases the number of neurospheres
due to enhanced neuronal stem cell survival, rather than increased
proliferation (Hunt et al., 2010).
The pharmacology of CsA is complex, and the drug binds a
family of cellular peptidyl-prolyl cis–trans isomerases known as
cyclophilins. Binding of CsA with the abundant cyclophilin A
leads to inhibition of calcineurin, a cytosolic phosphatase found
in many cell types, thus preventing dephosphorylation of its sub-
strates (Liu et al., 1991). A number of studies have shown that
calcineurin signals are involved in the control of myofiber size,
myofiber type, and skeletal muscle regeneration (Schiaffino and
Serrano, 2002; Sakuma and Yamaguchi, 2010; Hudson and Price,
2013). Although inhibition of calcineurin was shown to delay
muscle regeneration (Sakuma et al., 2003, 2005), literature stud-
ies investigating the outcomes of calcineurin inhibition by genetic
approaches or by CsA administration in animal models of muscle
diseases have produced contrasting results (Stupka et al., 2004; De
Luca et al., 2005; Parsons et al., 2007). The reasons for these dis-
crepancies rely upon multiple factors, including the genetic model
studied, the dose of the drug, the type of muscle, the duration
of treatment, and the route of treatment. For instance, the effi-
cacy of CsA in the mdx mice, an animal model of Duchenne
muscular dystrophy, was reported to be dependent on the dosage
and length of the treatment (Stupka et al., 2004; De Luca et al.,
2005). Notably, the protective effects of CsA in Col6a1−/− mice
do not rely upon calcineurin inhibition, as the same beneficial
effects are also displayed by non-immunosuppressive CsA analogs
that do not bind calcineurin, such as Debio 025 and NIM811
(Angelin et al., 2007; Zulian et al., 2014), whereas they cannot be
mimicked by the calcineurin inhibitor FK506 (Irwin et al., 2003).
Although our interest was far from the study of calcineurin activ-
ity, in this work we used a definite CsA dosage (5 mg/kg every
12 h, i.e., the same dose shown to be effective in rescuing differ-
ent aspects of the muscle pathology of Col6a1−/− mice), and this
dosage is known to only partially reduce the activity of calcineurin
(Dunn et al., 2002; Michel et al., 2004).
In conclusion, our results indicate that besides the already
known beneficial effects of CsA administration in ameliorating
the myophatic phenotype of Col6a1−/− mice through the rescue
from mitochondrial and autophagic dysfunction of muscle fibers,
CsA is also capable to stimulate muscle regeneration and preserve
the satellite cell pool in this disease model. These findings sup-
port and strengthen the increased muscle regeneration observed
in Ullrich patients undergoing clinical trial with CsA, pointing at
CsA and its non-immunosuppressive derivatives as a promising
therapeutic route for this group of inherited muscle diseases.
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